(Q39683562)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

title

Modulation of P-gp expression by lapatinib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sandra Roche

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Robert O'Connor

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

Gráinne Dunne

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Laura Breen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Martin Clynes

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

6 July 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

7 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

page(s)

1284-1293

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Structural, mechanistic and clinical aspects of MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Recent advances in the development of P-gp inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Development of taxane resistance in a panel of human lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Cytogenetic comparison of two poorly differentiated human lung squamous cell carcinoma lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Rapid and sensitive liquid chromatography-tandem mass spectrometry for the quantitation of epirubicin and identification of metabolites in biological samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9482-7

Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists.

21 January 2018

1 reference

12 December 2020

MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer

1 reference

12 December 2020

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

1 reference

12 December 2020

Acid phosphatase: endpoint for in vitro toxicity tests

1 reference

12 December 2020

Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

1 reference

12 December 2020

HER-2/neu expression: a major prognostic factor in endometrial cancer

1 reference

12 December 2020

Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer

1 reference

12 December 2020

The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.

1 reference

12 December 2020

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

1 reference

12 December 2020

10.1007/S10637-010-9482-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20607587%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference